NfL may be biomarker of response to Spinraza in early stages of SMA
Levels of neurofilament light chain (NfL) in bodily fluids may be a marker of response to treatment with Spinraza (nusinersen) in children with spinal muscular atrophy (SMA) in the early stages of disease, a new study reports. “NfL can be a valuable biomarker for reflecting disease activities, particularly…